MECOM and acute myeloid leukemia: To suppress EVI1-dependent GPR56 expression in EVI1high AML cells, in the present study, we developed PIPs, PIP/56-1 and PIP/56-2, that specifically target the EVI1-binding site within the GPR56 promoter15.